Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells - PubMed (original) (raw)
Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells
Doron Weinstein et al. Diabetes Metab Res Rev. 2009 Jan.
Abstract
Background: Insulin analogues are widely used in the treatment of diabetes mellitus. Some insulin analogues were reported to display atypical activities in vitro that resemble those of insulin-like growth factor-I (IGF-I). The aim of this study was to investigate whether two long-acting insulin analogues [glargine (Lantus, Sanofi Aventis, Germany) and detemir (Levemir, Novo Nordisk, Denmark)] and two short-acting analogues [lispro (Humalog, Eli Lilly, Indianapolis, USA) and aspart (Novolog, Novo Nordisk, Denmark)] exhibit IGF-I-like activities on cultured cancer cells in comparison with IGF-I and regular human insulin.
Methods: HCT-116 (colorectal cancer), PC-3 (prostate cancer) and MCF-7 (breast adenocarcinoma) cell lines were treated with insulin, IGF-I or insulin analogues, and proliferation and protection from apoptosis were measured by cell counting and fluorescent-activated cell sorter (FACS) analysis, respectively. In addition, Western blots were used to identify signalling molecules activated by the analogues.
Results: Glargine, detemir and lispro had proliferative effects that resemble IGF-I action. Insulin, however, did not stimulate cellular proliferation. In addition, glargine and detemir displayed an IGF-I-like anti-apoptotic activity. Glargine, like insulin and IGF-I, induced phosphorylation of both ERK and AKT, suggesting that the analogue is able to stimulate both the ras-raf-mitogen-activated protein kinase (MAPK) and PI3K-AKT pathways. Furthermore, glargine induced both insulin receptor (IR) and IGF-IR phosphorylation.
Conclusions: Glargine, detemir and lispro, unlike regular insulin, exhibit in vitro proliferative and anti-apoptotic activities in a number of cancer cell lines. These actions resemble some of the effects of IGF-I, a growth factor involved in cancer initiation and progression. Insulin had no increased IGF-I activity. The specific receptor/s involved in mediating analogues actions remains to be identified.
Copyright 2009 John Wiley & Sons, Ltd.
Comment in
- Appraising the mitogenicity of insulin analogues relative to human insulin-response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activity in cultured cancer cells. Diabetes Metab Res Rev 2009; 25(1): 41-9.
Kazda C, Slieker L, Ilag L, Byrd R, Rees T, Prince M. Kazda C, et al. Diabetes Metab Res Rev. 2010 Mar;26(3):145-9. doi: 10.1002/dmrr.1072. Diabetes Metab Res Rev. 2010. PMID: 20474066
Similar articles
- Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H. Yehezkel E, et al. Diabetologia. 2010 Dec;53(12):2667-75. doi: 10.1007/s00125-010-1899-1. Epub 2010 Sep 12. Diabetologia. 2010. PMID: 20835859 - Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
Hansen BF, Glendorf T, Hegelund AC, Lundby A, Lützen A, Slaaby R, Stidsen CE. Hansen BF, et al. PLoS One. 2012;7(5):e34274. doi: 10.1371/journal.pone.0034274. Epub 2012 May 8. PLoS One. 2012. PMID: 22590494 Free PMC article. - Appraising the mitogenicity of insulin analogues relative to human insulin-response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activity in cultured cancer cells. Diabetes Metab Res Rev 2009; 25(1): 41-9.
Kazda C, Slieker L, Ilag L, Byrd R, Rees T, Prince M. Kazda C, et al. Diabetes Metab Res Rev. 2010 Mar;26(3):145-9. doi: 10.1002/dmrr.1072. Diabetes Metab Res Rev. 2010. PMID: 20474066 - Update on insulin analogues.
[No authors listed] [No authors listed] Drug Ther Bull. 2004 Oct;42(10):77-80. doi: 10.1136/dtb.2004.421077. Drug Ther Bull. 2004. PMID: 15491022 Review.
Cited by
- Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
Pierre-Eugene C, Pagesy P, Nguyen TT, Neuillé M, Tschank G, Tennagels N, Hampe C, Issad T. Pierre-Eugene C, et al. PLoS One. 2012;7(7):e41992. doi: 10.1371/journal.pone.0041992. Epub 2012 Jul 26. PLoS One. 2012. PMID: 22848683 Free PMC article. - Diabetes and cancer: a consensus report.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Giovannucci E, et al. Diabetes Care. 2010 Jul;33(7):1674-85. doi: 10.2337/dc10-0666. Diabetes Care. 2010. PMID: 20587728 Free PMC article. - Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT. Hemkens LG, et al. Diabetologia. 2009 Sep;52(9):1732-44. doi: 10.1007/s00125-009-1418-4. Epub 2009 Jun 30. Diabetologia. 2009. PMID: 19565214 Free PMC article. - Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM; SDRN Epidemiology Group. Colhoun HM, et al. Diabetologia. 2009 Sep;52(9):1755-65. doi: 10.1007/s00125-009-1453-1. Epub 2009 Jul 15. Diabetologia. 2009. PMID: 19603149 Free PMC article. - Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer.
Kasprzak A. Kasprzak A. Int J Mol Sci. 2021 Jun 16;22(12):6434. doi: 10.3390/ijms22126434. Int J Mol Sci. 2021. PMID: 34208601 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous